SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 54362
  • 2
    Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 191924
  • 3
    Hill S, Khullar V, Wyndaele JJ, Lheritier K. Dose–response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 23947
  • 4
    Rogers R, Bachmann G, Jumadilova Z et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 15517
  • 5
    MacDiarmid SA. Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003; 4: 44651
  • 6
    Corcos J, Casey R, Patrick A et al. A double-blind randomized dose–response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006; 97: 5207
  • 7
    Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 30310
  • 8
    Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 4209
  • 9
    Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M-selective receptor antagonist. BJU Int 2005; 95: 5806
  • 10
    Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose–response in subjects with overactive bladder syndrome. Urology 2008; 71: 83943
  • 11
    Tubaro A, De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update 2004; 2: 1619
  • 12
    Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004; 29: 71520
  • 13
    Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11: 1327
  • 14
    Nilvebrant L. Clinical experiences with tolterodine. Life Sci 2001; 68: 254956
  • 15
    Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 28993
  • 16
    Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 120412
  • 17
    Nitti V, Dmochowski R, Sand P et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 248894
  • 18
    Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 107986
  • 19
    Sachse R, Cawello W, Haag MC, Horstmann R. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine. Arch Pharmacol 2003; 367: 446 [abstract]
  • 20
    Mukerji G, Yiangou Y, Grogono J et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006; 176: 36773
  • 21
    Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 428 [abstract]
  • 22
    Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 30714
  • 23
    Gomez A, Martos F, Bellido I et al. Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem Pharmacol 1992; 43: 24139
  • 24
    Irwin DE, Milsom I, Kopp Z, Abrams P. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 2008; 53: 102937
  • 25
    Sand PK, Steers WD, Dmochowski R, Andoh M, Forero-Schwanhaeuser S. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 66775
  • 26
    Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003; 92: 7315
  • 27
    Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006; 60: 74551
  • 28
    Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005; 22: 38194
  • 29
    Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zycyzynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005; 24: 21525
  • 30
    Brubaker L, Woodson K, Beach J et al. Self-Assessment Goal Achievement Questionnaire: baseline results of a pilot study in U.S. subjects with overactive bladder. In Society of Urologic Nurses and Associates 40th Annual Conference, 2009 October 2–5, 2009. Chicago, Illinois